Regular payments function is available
The world is closely monitoring the epidemiological situation related to the rise in human metapneumovirus cases in China.
Human metapneumovirus (MPV or metapneumovirus) is a virus that can cause respiratory illnesses in humans. First identified in 2001, it has since gained the attention of doctors and researchers as a potential cause of respiratory infections, particularly in children, the elderly, and individuals with weakened immune systems Metapneumovirus is one of the viruses that affect the respiratory system.
The primary mode of transmission is airborne—through coughing, sneezing, or contact with contaminated surfaces.
Symptoms of Metapneumovirus Infection
Infection with metapneumovirus can range from a mild cold to more severe conditions such as bronchitis and pneumonia. Symptoms may include:
Treatment and Prevention of Metapneumovirus
Treatment is mainly focused on symptom relief, as there is currently no specific antiviral therapy for metapneumovirus. Pain relievers and fever reducers are used to lower temperature and alleviate pain. Doctors may prescribe inhalations and mucolytics (medications that thin mucus) if the patient has a cough and breathing difficulties. Humidifying the air can help ease nasal congestion and coughing. In severe cases, such as in infants or elderly individuals, hospitalization may be required for more intensive treatment, including oxygen therapy.
Since metapneumovirus is transmitted through airborne droplets, several preventive measures can help reduce the risk of infection:
Like other viruses, metapneumovirus poses a greater risk to children under five—especially infants, whose respiratory systems are not fully developed. The elderly, particularly those with weakened immune systems or chronic conditions (such as heart or lung diseases), and individuals with compromised immunity (e.g., post-chemotherapy, HIV-positive individuals, or organ transplant recipients) are also at increased risk.